Related Experiment Video
Updated: Feb 7, 2026

A Nanobar-Supported Lipid Bilayer System for the Study of Membrane Curvature Sensing Proteins in vitro
Published on: November 30, 2022
Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?
Willibald Hochholzer1, Robert P Giugliano
1Universitaets-Herzzentrum Freiburg · Bad Krozingen, Suedring 15, 79189, Bad Krozingen, Germany. willibald.hochholzer@herzzentrum.de
Insights
Lowering cholesterol with statins is key for cardiovascular health. Combination therapies are being explored to further reduce residual risk when statins alone are insufficient.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Hypercholesterolemia is a primary risk factor for atherosclerotic diseases.
- Lowering cholesterol via lipid-lowering agents significantly reduces cardiovascular events and mortality.
- Statins are the current standard for cholesterol management due to their efficacy.
Purpose of the Study:
- To explore the potential of combination cholesterol-modifying therapies.
- To augment statin treatment effects and mitigate side effects.
- To address residual cardiovascular risk in patients inadequately managed by statin monotherapy.
Main Methods:
- Review of clinical trials and ongoing research in lipid-lowering therapies.
- Analysis of statin efficacy and limitations in achieving target cholesterol levels.
- Investigation of emerging combination treatment strategies.
Main Results:
- Statin monotherapy is effective but does not achieve target levels for all patients.
- Significant residual cardiovascular risk persists even with successful cholesterol lowering.
- No current evidence supports combination therapies improving clinical outcomes over statin monotherapy.
Conclusions:
- Combination therapies are of increasing interest for enhanced cholesterol management.
- Ongoing trials are crucial for evaluating the clinical utility of combination therapies.
- Further research is needed to establish the role of combination therapies in reducing residual cardiovascular risk.
Abstract:
Hypercholesterolemia is one of the main risk factors for the development of atherosclerotic diseases. Multiple clinical trials of lipid-lowering agents have demonstrated that lowering cholesterol effectively reduces the risk of cardiovascular events and death. Currently, treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") is the most commonly used approach, given their superior efficacy relative to other cholesterol lowering agents. However, not all patients on statin monotherapy achieve target cholesterol levels, and even when cholesterol lowering is successful, significant residual cardiovascular risk remains. There is increasing interest in developing combination cholesterol-modifying therapies that may augment the treatment effect and minimize the side effects of statins. Although there is currently no evidence that any of the potential therapy combinations can improve clinical outcome compared to statin monotherapy alone, results of several large ongoing trials will help to clarify this important field.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Aims Of Nursing
What are Lipids?
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Lipid Digestion

